Supernus Pharma (SUPN) Misses Q3 EPS by 94c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.80), $0.94 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $175.82 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Goldman Sachs on Kingsoft Cloud (KC): 'AI cloud to drive revenue expansion with attractive investment payback'
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short